Viewpoint on GMPs, Pharmaceutical Manufacturing, Systems Management, Regulatory Compliance and related Corporate Strategies.
Sunday, November 9, 2008
Recent Changes in GMP Rules
While a summary of the proposal was already published in details sometimes back in April (click here to read), Krishna Rao has also done a great favour in reviewing and preparing a comparative analysis of these changes in CFR 211. The review by Krishna is published in 'The Pharma Web Journal' and can be read or downloaded in acrobat.
Thursday, October 9, 2008
China and its Quality Control
Monday, September 15, 2008
National Seminar on “Road Map to the Indian Drug Industry”, 15th – 16th September, 2008
The seminar was inaugurated by the Chief Minister of Andhra Pradesh Dr Y Rajasekhar Reddy by liting lamp along with Dr. K Anji Reddy, Chairman Dr Reddy's Laboratories Limited. Dr. K. Anji Reddy was felicitated by Chief Minister by presenting a shawl as a souvenir.Speakers in the seminar from different disciplines of Drugs & Pharmaceuticals industry shared their experiences, thoughts and contemporary trends in the fields of drug discovery, IPR, International developments, Manufacturing, GMPs, SHE, IT and Automation.
The most inspiring speech was made by Dr K Anji Reddy in which he informed the audience of his experience, efforts and strategies of tilting the export balance of APIs in India’s favor. In his witty style, he narrated how Dr Reddy’s Labs thought of the IPR regime well in advance and prepared for the drug discovery research.
On the second day of seminar, CEO of Dr Reddy’s, Mr. GV Prasad highlighted the importance of sustainability. At the backdrop of world wide financial & business fluctuation, rise and fall of oil prices and capability of Chinese manufacturers, Mr. GV Prasad explained the audience for the available alternatives. Amidst the challenges to the Indian Pharma companies, he shared his innovative idea of ‘seeing quality from different angle’ and therefore, as an effort for this, how Dr Reddy’s is being benefited by a Japanese consultant who is from an engineering industry background. Mr. GV Prasad also informed about the efforts being made by Dr Reddy’s on Strategic Partners side wherein the company is working for the development of their vendors as a win-win model.
The other eminent speakers include APSIDC MD, MR BP Acharya (IAS), Mr. Sam Bob (IAS), Principal Secretary; Ministry of Commerce who explained the general industrial policy of the state and in particular to SEZs which are being developed.
While, Dr. Lalji Singh from CCMB described the challenges and opportunities available through stem cell research, Dr. Venkatswaralu (former Drug Controller General) emphasized on meeting GMP requirements. Dr. Venkatswaralu highlighted the importance of Human Resource vis-à-vis continuous training and development. He underlines the concerns on ambiguities and inadequacies in GMP documents. He asked the forum that how many companies are auditing Chinese manufacturers and suppliers. He wondered that should we also wait for a Heparin type incident to initiate that.
The other important speakers were Dr. Sengupta (Member Secretary, CPCB and Planning Commission), Mr. Kjell Olsen from GTZ, Mr. S. Mani (VP-SHE, Orchid), and Mr. P Shamugama Sundram from TUV and Rajiv Sodhi from Microsoft.
The seminar presented a vista of information. On one side government policies on infrastructural development and support were conveyed, on the other side the challenges of the next decade were discussed. Mr. P Shamugama Sundram from TUV deliberated the latest requirement of REACH certification as per the new European directive 1907/2006. He further explained the difference between MSDS and CSR requirements for chemical industries.
Monday, July 28, 2008
Regulatory Agencies and the End of Innovation
When FDA first published its visionary paper on 21st Century Initiatives, it's purpose was to give direction to the innovation in technology and management for fully (current) grown pharmaceutical industry. Besides this, the other initiatives which FDA and other regulatory agencies have taken, namely PAT, risk based approach and defining quality systems in GMP prespective are all moving in the same direction of innovation and gives logical interpretation of quality systems management. Though much of it has been said, but nothing substantial has moved on the floor - particularly in India!
ICH is primarily engaged in integrating the current global pharmaceutical quality and related philosophies and practices. However, the newly published ICH Q9 and Q10 speaks of something which was already existing into the innovation hungry pharmaceutical industry. The application of 'risk assessment' and 'quality systems' do not offer anything new. My view point on these developments is this, that it is almost a decade after the advent of 'International GMPs' in India, there is nothing new which is emerging. The cross-functional reviews and the system controls like - Change Control, Incidents handling, APQR and CAPA are still living their life to full.
I don't remember any regulatory inspector asking for the risk assessment details for any drug development process till its commercial launch!
The FDAs 21st century approach and PAT also emphasise on automation and innovation, but nothing substantial has really moved on these fronts at least in India. There appears few seminar brochures giving details on discussions on these topics, few articles appearing in prominent international journals - but nothing beyond that. I am not so sure of European and American companies for imbibing PAT into their regular practices.
The same is the fate of Six sigma or Lean management for pharma industry. We live with the concepts and when the implementation comes - we wait for the regulatory compulsions to arrive.
The question here is - why so many thoughts but no applications ? Have we reached the saturation in terms of implemneting quality systems? Does too much of expectations are distancing the innovation ?
Monday, July 21, 2008
US FDA in India - So What !

However, in this process, the complete focus of a company is not on the quality of products being manufactured or quality systems, but on how to successfully appease the visiting auditors. This, therefore, takes a narrow approach which undermines the ethos of quality philosophy.
Now the recent news that FDA is planning to open their regional offices in India or China is creating hype in industry.After all our long relationship with FDA (in facing large number of audits) has still not taught us anything new. Even the 21st centry approach, the vision documents from FDA seems to be irrlevant. There are no lessons learned from our past experiences.
And so is the worry that FDA is planning its base in your own city.
Thursday, June 12, 2008
Break from Blogging
-------------------------------------------------------------------------------------------------
Forthcoming - Acquasition of Ranbaxy and future of Regulated Companies in India.
Wednesday, April 30, 2008
Ideas never die and Invention of Quality!
I remember entering the room of a Manager of one pharma company which was tidy, neat and well maintained. The placement of pens and pencils in the pen holder, colours, sketch pens, books, charts and chair - in fact everything was wonderful. Or did I only think that was wonderful ? My attitude or his attitude ?
Alfred Nobel, so distress from his invention of dynamite, raised his wealth for an award - Nobel prize. He thought rather unusual - a quality thought? Does thoughts also have quality ?
But had he never had so much of wealth to offer, what Alfred would have done?? No money - no award. The quality of Life...
You never know - quality is multidimensional, multifaceted, omnipresent and mysteriously hidden in the seed of human thoughts - human thought which have the courage to raise this civilization! Is it?
Is quality an Idea ?
Saturday, April 5, 2008
Column Equivalency Tool at USP
The USP procedure uses the parity among the parameters like CTF (Chelating Tailing Factor); CFA (Capacity Factor Amitryptiline); TFA (Tailing Factor Amitryptiline) & BD (Bonding Density) to arrive at the possible alternatives;
PQRI uses the comparison of Column hydrophobicity (H); Column Steric Interaction (S); Column Hydrogen-bond Acidity (A); Column Hydrogen-Bond Basicity (B) & Column Ion-Exchange Capacity (C) as the basis for calculating equivalence
The USP Column listing is essentially the compendial columns (listed in USP-NF) - whereas the PQRI listing is bigger & not specific to compendial columns..
To accessed the toold, click here (both USP & PQRI column listings)
Sunday, March 30, 2008
Quality is free -
But is quality really free ?? If so then what it the Cost of Quality ?
Nevertheless, what is freely available in the efforts of perfection - are the innovative thoughts of systematic approach and logical methodologies.
Saturday, March 15, 2008
FDA Proposes its Office in China
In earlier news last year, the FDA was planning to open their office in one of the city in India preferably at Hyderabad. However, what conspired in the galleries is not known.
This is despite of the fact, that recent Baxter’s Heparin case where four people died was originally manufactured in China.
As more and more Indian companies are inching towards generic drugs multinationals, the FDA is tightening its noose over these companies while relaxing its standards towards Chinese drug manufacturers where from sources known that getting a GMP certificate takes only 7 days!!!
It is not known that whether it is economic pressures, technological issues or the diplomatic appeasement.
Sunday, March 2, 2008
When fears go wrong...
Much of that fear has already lost withn last 3 years. On the contarary, the MNCs operating in India from at least last 40 to 50 years have eroded their market captelisation.
The Pfizer, Novartis and Merck have all lost the glory of their past days operation in India. With nothing much to offer from their global new product basket, these companies continue to struggle over pricing issues.
To read the complete storey published in Economic Times, click here.
Saturday, March 1, 2008
Integrated CAPA Approach, as a key model for Quality Systems
It was rather 5 years back, when the concpet of integrating all deficiencies capturing tools with a single investigative and managing tool - CAPA came into thought. Though I had conceptuliased this idea, but its writing it down only took this much of time! The idea is that -CAPA can be developed as a single logbook concept, wherein all the deficiencies are listed, investigated and reviewed. This is good approach of reducing these identified deficiencies as a part of achieving total quality. I am giving the abstract of this article whereas to read the complete article and understand the integrated CAPA approach, click here.Thursday, February 28, 2008
FDA Inspects wrong plant in China
And we thought- it happens only in India !
Saturday, February 23, 2008
Container & Closure Integrity in Lieu of Sterility Testing in Stability Protocol
Sunday, February 10, 2008
Integration of GMPs and Quality Management Systems - ICH Q10
The Quality System shall ensure conformity of each manufactured medicinal product with the quality as specified in the product's marketing authorisation / registration.
Elements like Corrective and Preventive Action (CAPA) and Continual Improvement are covered as well as Management responsibilities and Design Control.
Thursday, January 24, 2008
The Indian Pharmacopoeia - 2007
The new IP is released in three volumes with 300 monographs and many new features. Besides, the 175 new monographs of chemicals and dosage forms, it has monographs on vaccines, immunosera, herbs, herbal products, blood and blood-related products, biotechnology and veterinary products.
In the fifth version Categories of a drug, dosage & usual available strength of dosage forms have been omitted. Classical chemical tests for identification of an article have been almost eliminated & more specific IR & UV spectrophotometric tests have been introduced.
There is more emphasis on Use of Chromatographic methods which has been greatly extended to cope with the need for more specificity in assays and test for pyrogens were virtually eliminated. The BET (bacterial endotoxin test) are going to be applicable to more items.
Saturday, January 19, 2008
The 21st Century QA, Part-I
After carefully reviewing the concept paper released by FDA and ICH on 21st century GMPs or the quality systems it clearly reflects the view points of these agencies for future quality systems management, particularly in pharmaceutical industry. These guidance's describes the comprehensive quality systems model, which, if implemented, will allow manufacturers to operate robust, modern quality systems that are fully compliant with cGMP regulations. The overarching philosophy philosophy articulated in these guidelines is Quality should be built into the product, and testing alone cannot be relied on to ensure product quality. This statement in fact lay down the future prespective of quality systems in the pharmaceutical industry.
Therefore, it is now the onus of quality professionals to realise the visionary statement which emphasizes on building quality into the products rather then working for quality.The rapid growth of pharma industry into the international markets is phenomenal and the participation of this industry into generic business is even more significant.
It is my belief, that with a pace the pharma industry is moving and expanding, many a times it also becomes difficult to manage the entire operations keeping the options open. India had not seen such economic expansion of industry, markets and business till last decade. It's a high time, great time and also time for introspection! We need to think of innovative ideas which are indigenous and compatible to our needs and fulfil the concept of quality by design. Now, it is a collective responsibility of companies and the stalwarts of industry to re-design the Quality Systems and their approach towards quality. We have moved ahead from the earlier stages of maturity. The concepts are not new to the industry and above all their is an immense wealth of experience in managing technology, operations, management and systems.My firend may have other different reasons also to make quick changes in job, but, the after effects of our dialogue and then followed by introspection opened new gateway of ideas giving birth to -quality process re-engineering.In my subsequent writings, I will be giving more information on the GMPs, which is much easier to practice, implement and above all productive !!
Thursday, January 17, 2008
GAMP 5 on Desks -
There has also been a major move toward the use of products and packaged solutions and away from bespoke developments.
As a result the GAMP Council is planning to revise the GAMP Guide to reflect current regulatory expectations and current industry good practice while maintaining continuity with GAMP 4 principles. The Guide will be focus on the use of products and packaged solutions rather than custom (bespoke) systems.
The emphasis will be on providing a cost effective approach to validation that will demonstrate that a computerized system is fit for its intended use, while avoiding unnecessary work. To support this, new and updated guidance is in development on the following aspects:
- Scaleable validation approach driven by risk to product quality, patient safety and regulatory compliance including supporting records.
- Integration of validation activities within a complete life cycle approach as part of a Quality Management System (QMS), from concept through development and operation to retirement.
- Use of supplier documentation and knowledge wherever possible to avoid repetition and duplication.
- Importance of clear requirements based on a thorough understanding of the process and product.
- Improving validation efficiency by enabling practical and efficient interpretation of GAMP guidance
Concepts and terminology will be aligned with recent regulatory developments including:
- FDA cGMPs for the 21st Century Initiative and associated guidance.
- PIC/S Guidance.
- ICH (International Council for Harmonization) Guidance Q9 and Q10.
- Emerging standards such as those produced by the ASTM E55 Committee
Source : ISPE, GAMP COP.